DK3592392T3 - Fasl-manipulerede biomaterialer med immunomodulatorisk funktion - Google Patents

Fasl-manipulerede biomaterialer med immunomodulatorisk funktion Download PDF

Info

Publication number
DK3592392T3
DK3592392T3 DK18764623.7T DK18764623T DK3592392T3 DK 3592392 T3 DK3592392 T3 DK 3592392T3 DK 18764623 T DK18764623 T DK 18764623T DK 3592392 T3 DK3592392 T3 DK 3592392T3
Authority
DK
Denmark
Prior art keywords
fasl
biomaterials
manipulated
immunomodulatory function
immunomodulatory
Prior art date
Application number
DK18764623.7T
Other languages
English (en)
Inventor
Haval Shirwan
Andres J Garcia
Esma S Yolcu
Hong Zhao
Devon Headen
Original Assignee
Univ Louisville Res Found Inc
Georgia Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisville Res Found Inc, Georgia Tech Res Inst filed Critical Univ Louisville Res Found Inc
Application granted granted Critical
Publication of DK3592392T3 publication Critical patent/DK3592392T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/39Pancreas; Islets of Langerhans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178Lectin superfamily, e.g. selectins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00Tissue, human, animal or plant cell, or virus culture apparatus
    • C12M3/02Tissue, human, animal or plant cell, or virus culture apparatus with means providing suspensions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
DK18764623.7T 2017-03-10 2018-03-09 Fasl-manipulerede biomaterialer med immunomodulatorisk funktion DK3592392T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469802P 2017-03-10 2017-03-10
PCT/US2018/021742 WO2018165547A1 (en) 2017-03-10 2018-03-09 Fasl-engineered biomaterials with immunomodulatory function

Publications (1)

Publication Number Publication Date
DK3592392T3 true DK3592392T3 (da) 2023-10-23

Family

ID=63448048

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18764623.7T DK3592392T3 (da) 2017-03-10 2018-03-09 Fasl-manipulerede biomaterialer med immunomodulatorisk funktion

Country Status (17)

Country Link
US (2) US11602547B2 (da)
EP (2) EP4299749A3 (da)
JP (1) JP7335821B2 (da)
CN (1) CN110582560B (da)
AU (1) AU2018230474B2 (da)
CA (1) CA3055908A1 (da)
DK (1) DK3592392T3 (da)
ES (1) ES2963331T3 (da)
FI (1) FI3592392T3 (da)
HR (1) HRP20231297T1 (da)
HU (1) HUE064306T2 (da)
LT (1) LT3592392T (da)
PL (1) PL3592392T3 (da)
PT (1) PT3592392T (da)
RS (1) RS64754B1 (da)
SI (1) SI3592392T1 (da)
WO (1) WO2018165547A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202104337PA (en) * 2018-11-26 2021-05-28 Massachusetts Inst Technology Compositions and methods for immune tolerance
AU2021306315A1 (en) * 2020-07-08 2023-03-02 Georgia Tech Research Corporation Crosslinked hydrogel for immune checkpoint blockade delivery
WO2023220690A1 (en) * 2022-05-12 2023-11-16 Itolerance, Inc. Transient sirolimus with fasl microgels

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022951A (en) 1995-04-11 2000-02-08 Univ Boston Streptavidin mutants
AU724856B2 (en) * 1995-06-30 2000-10-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds
US7927602B2 (en) * 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
US7238360B2 (en) 2000-06-30 2007-07-03 Unversity Of Louisville Research Foundation, Inc. Alteration of cell membrane with B7
AU2003297573A1 (en) * 2002-11-27 2004-06-23 Cedric Francois Compositions and methods for treating transplants
AU2006279541A1 (en) * 2005-08-15 2007-02-22 The Regents Of The University Of California VEGF-activated FAS ligands
WO2011041240A1 (en) * 2009-09-30 2011-04-07 The Brigham And Women's Hospital, Inc. Tissue transplant compositions and methods for use
PL2459220T3 (pl) 2009-07-31 2021-03-08 Ascendis Pharma A/S Biodegradowalne nierozpuszczalne w wodzie hydrożele na bazie poli(glikolu etylenowego)
CN102781436B (zh) * 2009-11-06 2014-01-08 爱思开生物制药株式会社 纤维肌痛综合征的治疗方法
MY178680A (en) 2012-10-11 2020-10-20 Ascendis Pharma As Hydrogel prodrugs
WO2015034928A1 (en) * 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9381217B2 (en) 2013-09-09 2016-07-05 Georgia Tech Research Corporation Microgels for encapsulation of cells and other biologic agents
WO2016205714A1 (en) 2015-06-19 2016-12-22 University Of Louisville Research Foundation, Inc. Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection

Also Published As

Publication number Publication date
AU2018230474B2 (en) 2023-08-03
US11602547B2 (en) 2023-03-14
HRP20231297T1 (hr) 2024-02-02
HUE064306T2 (hu) 2024-02-28
US20230310510A1 (en) 2023-10-05
EP3592392A4 (en) 2020-12-16
AU2018230474A1 (en) 2019-10-31
EP4299749A2 (en) 2024-01-03
ES2963331T3 (es) 2024-03-26
JP7335821B2 (ja) 2023-08-30
CN110582560B (zh) 2024-06-14
LT3592392T (lt) 2024-01-25
US20200046780A1 (en) 2020-02-13
PL3592392T3 (pl) 2024-03-18
SI3592392T1 (sl) 2024-02-29
CN110582560A (zh) 2019-12-17
EP3592392B1 (en) 2023-09-13
EP4299749A3 (en) 2024-03-27
RS64754B1 (sr) 2023-11-30
PT3592392T (pt) 2023-11-23
EP3592392A1 (en) 2020-01-15
FI3592392T3 (fi) 2023-11-09
JP2020511531A (ja) 2020-04-16
WO2018165547A1 (en) 2018-09-13
CA3055908A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
DK3435933T3 (da) Stomifastgørelse
DK3400926T3 (da) Stimulationsindretning med forlængelse
DK3137843T3 (da) Projektil med forbedret ballistik
DK3297295T3 (da) Høreanordning med fastgørelsesanordning
BR112017021852A2 (pt) ferramenta de anexação de sensor.
DK3709940T3 (da) Beholdere med rivningstyrende egenskaber
DK2941019T3 (da) Høreapparat med fjern-objektdetekteringsenhed
DK3592392T3 (da) Fasl-manipulerede biomaterialer med immunomodulatorisk funktion
DK3269153T3 (da) Øregangshøreapparater med forbedrede forseglinger
DK3248522T3 (da) Indbygget alkove med dør
ES1196087Y (es) Dispositivo de introduccion de cateter
ES1194610Y (es) Dispositivo mecanico de representacion haptica-3d
MA49558A (fr) Dérivativés de 2-oxo-1-imidazolidinyl imidazothiadiazole
ES1187060Y (es) Bolardo de caucho
IT201700112270A1 (it) Pbox-PORTA AURICOLARE
ES1187034Y (es) Pieza de silcona
CL2017001054S1 (es) Placa de cocina cuatro fuegos
DK3404307T3 (da) Fitting
DK3404308T3 (da) Fitting
UA35508S (uk) Двері
UA35515S (uk) Двері
UA35431S (uk) Двері
UA35507S (uk) Двері
UA35435S (uk) Двері
UA35429S (uk) Двері